Evidence map›Paper›PMID 35259918›Full record

Trial reportCirculation2022

Comprehensive Quality-of-Life Outcomes With Invasive Versus Conservative Management of Chronic Coronary Disease in ISCHEMIA.

Daniel B Mark, John A Spertus, Robert Bigelow, Sophia Anderson, Melanie R Daniels, Kevin J Anstrom, Khaula N Baloch, David J Cohen, Claes Held, Shaun G Goodman and 9 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01471522 (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01471522 nacompletednot on this map

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

TypeinterventionalSponsorNYU Langone HealthRan2012 to 2023Enrolled5,179ConditionsCardiovascular Diseases, Coronary Disease, Coronary Artery Disease, Heart DiseasesArmscardiac catheterization, coronary artery bypass graft surgery, percutaneous coronary intervention, Lifestyle, Medication
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Influence of Pullback Pressure Gradient on Residual Angina at One Year.Circulation. Cardiovascular interventions · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Quantitative flow ratio as a continuous predictor of myocardial infarction.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2023
    Article
  12. Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 4 countries.

Daniel B MarkDuke Clinical Research Institute, Duke University, Durham, NC (D.B.M., R.B., S.A., M.R.D., K.J.A., K.N.B., D.C., K.P.A.).ORCID 0000-0001-6340-8087
John A SpertusSaint Luke's Mid America Heart Institute/University of Missouri, Kansas City (J.A.S.).ORCID 0000-0002-2839-2611
Robert BigelowDuke Clinical Research Institute, Duke University, Durham, NC (D.B.M., R.B., S.A., M.R.D., K.J.A., K.N.B., D.C., K.P.A.).
Sophia AndersonDuke Clinical Research Institute, Duke University, Durham, NC (D.B.M., R.B., S.A., M.R.D., K.J.A., K.N.B., D.C., K.P.A.).
Melanie R DanielsDuke Clinical Research Institute, Duke University, Durham, NC (D.B.M., R.B., S.A., M.R.D., K.J.A., K.N.B., D.C., K.P.A.).
Kevin J AnstromDuke Clinical Research Institute, Duke University, Durham, NC (D.B.M., R.B., S.A., M.R.D., K.J.A., K.N.B., D.C., K.P.A.).
Khaula N BalochDuke Clinical Research Institute, Duke University, Durham, NC (D.B.M., R.B., S.A., M.R.D., K.J.A., K.N.B., D.C., K.P.A.).ORCID 0000-0003-2257-0234
David J CohenCardiovascular Research Foundation, New York (D.J.C.).ORCID 0000-0001-9163-724X
Claes HeldDepartment of Medical Sciences, Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden (C.H.).ORCID 0000-0001-9402-7404
Shaun G GoodmanSt. Michael's Hospital, University of Toronto, and Canadian Heart Research Centre, Ontario, Canada (S.G.G.).ORCID 0000-0001-8068-2440
Sripal BangaloreNYU Grossman School of Medicine, New York (S.B., H.R.R., J.S.H.).ORCID 0000-0001-9485-0652
Derek CyrDuke Clinical Research Institute, Duke University, Durham, NC (D.B.M., R.B., S.A., M.R.D., K.J.A., K.N.B., D.C., K.P.A.).
Harmony R ReynoldsNYU Grossman School of Medicine, New York (S.B., H.R.R., J.S.H.).ORCID 0000-0003-0284-0655
Karen P AlexanderDuke Clinical Research Institute, Duke University, Durham, NC (D.B.M., R.B., S.A., M.R.D., K.J.A., K.N.B., D.C., K.P.A.).ORCID 0000-0003-4418-1424
Yves RosenbergNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (Y.R.).
Gregg W StoneThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York (G.W.S.).ORCID 0000-0002-3416-8210
David J MaronDepartment of Medicine, Stanford University School of Medicine, CA (D.J.M.).
Judith S HochmanNYU Grossman School of Medicine, New York (S.B., H.R.R., J.S.H.).ORCID 0000-0002-5889-5981
ISCHEMIA Research Group
Duke University · USNew York University · USCardiovascular Institute of the South · USNational Institutes of Health · USSaint Luke's Hospital · USStanford University · USSt. Francis Hospital · USSt. Michael's Hospital · CAUppsala University · SE

Funding

Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5M
The Ischemia Trial - CCCU01HL105907 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HOCHMAN, JUDITH S · 2011 to 2019
$100.1M
The ISCHEMIA Trial - SDCCU01HL105462 · NHLBI · DUKE UNIVERSITY · PI ALEXANDER, KAREN P, O'BRIEN, SEAN M · 2011 to 2019
$17.8M
THE ISCHEMIA TRIAL - IICCU01HL105561 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SHAW, LESLEE J · 2011 to 2018
$6.5M
The ISCHEMIA Trial - EQOLU01HL105565 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2011 to 2017
$2.4M
NCATS NIH HHS UL1 TR001445NHLBI NIH HHS U01 HL105462NHLBI NIH HHS U01 HL105561NHLBI NIH HHS U01 HL105565NHLBI NIH HHS U01 HL105907
6 · The paper itself

Abstract

backgroundISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) compared an initial invasive treatment strategy (INV) with an initial conservative strategy in 5179 participants with chronic coronary disease and moderate or severe ischemia. The ISCHEMIA research program included a comprehensive quality-of-life (QOL) substudy.

methodsIn 1819 participants (907 INV, 912 conservative strategy), we collected a battery of disease-specific and generic QOL instruments by structured interviews at baseline; at 3, 12, 24, and 36 months postrandomization; and at study closeout. Assessments included angina-related QOL (19-item Seattle Angina Questionnaire), generic health status (EQ-5D), depressive symptoms (Patient Health Questionnaire-8), and, for North American patients, cardiac functional status (Duke Activity Status Index).

resultsMedian age was 67 years, 19.2% were female, and 15.9% were non-White. The estimated mean difference for the 19-item Seattle Angina Questionnaire Summary score favored INV (1.4 points [95% CI, 0.2-2.5] over all follow-up). No differences were observed in patients with rare/absent baseline angina (SAQ Angina Frequency score >80). Among patients with more frequent angina at baseline (SAQ Angina Frequency score <80, 744 patients, 41%), those randomly assigned to INV had a mean 3.7-point higher 19-item Seattle Angina Questionnaire Summary score than conservative strategy (95% CI, 1.6-5.8) with consistent effects across SAQ subscales: Physical Limitations 3.2 points (95% CI, 0.2-6.1), Angina Frequency 3.2 points (95% CI, 1.2-5.1), Quality of Life/Health Perceptions 5.3 points (95% CI, 2.8-7.8). For the Duke Activity Status Index, no difference was estimated overall by treatment, but in patients with baseline SAQ Angina Frequency scores <80, Duke Activity Status Index scores were higher for INV (3.2 points [95% CI, 0.6-5.7]), whereas patients with rare/absent baseline angina showed no treatment-related differences. Moderate to severe depression was infrequent at randomization (11.5%-12.8%) and was unaffected by treatment assignment.

conclusionsIn the ISCHEMIA comprehensive QOL substudy, patients with more frequent baseline angina reported greater improvements in the symptom, physical functioning, and psychological well-being dimensions of QOL when treated with an invasive strategy, whereas patients who had rare/absent angina at baseline reported no consistent treatment-related QOL differences. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT01471522.

Indexed as

Coronary DiseaseQuality of LifeAgedAngina PectorisChronic DiseaseConservative TreatmentFemaleHumansIschemiaMaleangina pectoriscoronary angiographycoronary artery bypasscoronary diseasehealth statusmyocardial ischemiamyocardial revascularizationquality of life

Identifiers

PMID35259918
PMCPMC9044280
OpenAlexW4220731723

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.